

**Table S1. Predictors of Extracellular Volume Status (Percentage Volume Expansion, %VE)**

|                                                   | Univariate Analysis                           |         | Multivariate Analysis <sup>§</sup>            |         |
|---------------------------------------------------|-----------------------------------------------|---------|-----------------------------------------------|---------|
|                                                   | Regression Coefficient (95% CI <sup>°</sup> ) | p-value | Regression Coefficient (95% CI <sup>°</sup> ) | p-value |
| (***S) Sodium intake (mg)                         | 1.8 (1.3, 2.3)                                | <0.001  | 1.7 (1.2, 2.4)                                | <0.001  |
| (***S) Fluid intake (mL)                          | 1.4 (0.6, 2.0)                                | <0.001  |                                               |         |
| (**S) Age (years)                                 | 1.9 (0.9, 2.8)                                | <0.001  | 1.8 (1.0, 2.6)                                | <0.001  |
| <b>Presence of diabetes</b>                       |                                               |         |                                               |         |
| Non-diabetic                                      | 0                                             | <0.001  |                                               |         |
| NODAT                                             | 2.4 (-1.2, 5.9)                               |         |                                               |         |
| Pre-DM                                            | 10.3 (6.0, 14.7)                              |         |                                               |         |
| <b>Gender</b>                                     |                                               |         |                                               |         |
| Female                                            | 0                                             | 0.002   |                                               |         |
| Male                                              | 4.3 (1.6, 7.0)                                |         |                                               |         |
| <b>Use of ACEI / ARB</b>                          |                                               |         |                                               |         |
| No                                                | 0                                             | 0.01    |                                               |         |
| Yes                                               | 3.6 (0.9, 6.3)                                |         |                                               |         |
| Number of antihypertensive medications            | 1.6 (0.1, 3.2)                                | 0.04    |                                               |         |
| Alb (g/L)                                         | -0.4 (-0.8, 0.1)                              | 0.11    |                                               |         |
| <b>Use of diuretic (furosemide)</b>               |                                               |         |                                               |         |
| No                                                | 0                                             | 0.11    |                                               |         |
| Yes                                               | 3.5 (-0.8, 7.8)                               |         |                                               |         |
| (*) FTI (kg/m <sup>2</sup> )                      | -1.0 (-2.0, 0.5)                              | 0.12    | -1.4 (-2.2, -0.5)                             | 0.002   |
| (*) eGFR (mL/min)                                 | -0.3 (-0.6, 0.1)                              | 0.19    |                                               |         |
| (†) ACR (mg/mmol)                                 | 0.5 (-0.4, 1.4)                               | 0.27    |                                               |         |
| <b>*Ethnicity</b>                                 |                                               |         |                                               |         |
| Caucasian                                         | 0                                             | 0.29    |                                               |         |
| Non-Caucasian                                     | -1.8 (-5.1, 1.5)                              |         |                                               |         |
| <b>Use of prednisolone</b>                        |                                               |         |                                               |         |
| No                                                | 0                                             | 0.29    |                                               |         |
| Yes                                               | -1.8 (-5.1, 1.6)                              |         |                                               |         |
| (*) LTI (kg/m <sup>2</sup> )                      | -0.2 (-0.7, 0.2)                              | 0.31    |                                               |         |
| <b>†Smoking status</b>                            |                                               |         |                                               |         |
| Never smoked                                      | 0                                             | 0.32    |                                               |         |
| Ex-smoker / Current smoker                        | 0.1 (-1.4, 4.3)                               |         |                                               |         |
| <b>Use of BAB</b>                                 |                                               |         |                                               |         |
| No                                                | 0                                             | 0.34    |                                               |         |
| Yes                                               | 0.2 (-1.3, 3.9)                               |         |                                               |         |
| <b>Use of CCB</b>                                 |                                               |         |                                               |         |
| No                                                | 0                                             | 0.34    |                                               |         |
| Yes                                               | 0.1 (-1.5, 4.1)                               |         |                                               |         |
| Hb (g/dL)                                         | -0.4 (-1.3, 0.5)                              | 0.44    |                                               |         |
| <b>Use of AAB</b>                                 |                                               |         |                                               |         |
| No                                                | 0                                             | 0.52    |                                               |         |
| Yes                                               | 0.1 (-2.0, 3.9)                               |         |                                               |         |
| (*) Time post transplantation (years)             | 0.2 (-0.9, 1.3)                               | 0.76    |                                               |         |
| <b>Use of calcineurin inhibitor</b>               |                                               |         |                                               |         |
| No                                                | 0                                             | 0.85    |                                               |         |
| Yes                                               | -0.3, (-3.7, 3.1)                             |         |                                               |         |
| (†) hsCRP (mg/L)                                  | 0.1 (-1.3, 1.4)                               | 0.94    |                                               |         |
| <b>Previous episodes of acute rejection</b>       |                                               |         |                                               |         |
| No                                                | 0                                             | 0.95    |                                               |         |
| Yes                                               | -0.1 (-3.4, 3.2)                              |         |                                               |         |
| <b>Use of adjunctive antiproliferative agents</b> |                                               |         |                                               |         |
| No                                                | 0                                             | 0.99    |                                               |         |
| Yes                                               | -0.0 (-4.6, 4.5)                              |         |                                               |         |
| <b>R<sup>2</sup> value from final model</b>       |                                               |         | <b>51%</b>                                    |         |

<sup>§</sup>Results in the final multivariate regression model were presented.

<sup>°</sup>CI = Confidence Interval.

<sup>†</sup>For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients respectively.

<sup>‡</sup>For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.

(\*) Coefficients reported for a 5-unit increase in explanatory variable.

(\*\*) Coefficients reported for a 10-unit increase in explanatory variable.

(\*\*\*) Coefficients reported for a 50-unit increase in explanatory variable.

(†) Variable analysed on the log scale (base 10).

Abbreviations: %VE=Percentage Volume Expansion; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; Alb=Albumin; FTI=Fat Tissue Index; eGFR=estimated Glomerular Filtration Rate; ACR=Albumin : Creatinine Ratio; LTI= Lean Tissue Index; BAB=Beta-Adrenergic Blocker; CCB=Calcium Channel Blocker; Hb=Haemoglobin; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein.

**Table S2. Predictors of Mean Arterial Pressure (MAP)**

|                                                    | Univariate Analysis                           |         | Multivariate Analysis <sup>§</sup>            |         |
|----------------------------------------------------|-----------------------------------------------|---------|-----------------------------------------------|---------|
|                                                    | Regression Coefficient (95% CI <sup>¶</sup> ) | p-value | Regression Coefficient (95% CI <sup>¶</sup> ) | p-value |
| ( <sup>¶</sup> ) %VE                               | 6.6 (5.6, 7.5)                                | <0.001  | 6.6 (5.6, 7.6)                                | <0.001  |
| ( <sup>***</sup> ) Sodium intake (mg)              | 0.3 (0.2, 0.4)                                | <0.001  |                                               |         |
| ( <sup>**</sup> ) Age (years)                      | 2.5 (0.9, 4.1)                                | <0.01   |                                               |         |
| <b>Presence of diabetes</b>                        |                                               |         |                                               |         |
| Non-diabetic                                       | 0                                             | <0.01   |                                               |         |
| NODAT                                              | 5.6 (2.1, 9.0)                                |         |                                               |         |
| Pre-DM                                             | 11.2 (2.8, 19.5)                              |         |                                               |         |
| <b>Use of ACEI / ARB</b>                           |                                               |         |                                               |         |
| No                                                 | 0                                             | <0.01   |                                               |         |
| Yes                                                | 6.7 (2.1, 11.3)                               |         |                                               |         |
| Alb (g/L)                                          | -0.9 (-1.7, -0.2)                             | 0.01    |                                               |         |
| <b>Gender</b>                                      |                                               |         |                                               |         |
| Female                                             | 0                                             | 0.02    |                                               |         |
| Male                                               | 5.8 (1.1, 10.4)                               |         |                                               |         |
| ( <sup>***</sup> ) Fluid intake (mL)               | 0.2 (0.0, 0.3)                                | 0.03    |                                               |         |
| Number of antihypertensive medications             | 2.7 (0.0, 5.4)                                | 0.05    |                                               |         |
| <b><sup>‡</sup>Ethnicity</b>                       |                                               |         |                                               |         |
| Caucasian                                          | 0                                             | 0.08    |                                               |         |
| Non-Caucasian                                      | 5.0 (-0.5, 11.0)                              |         |                                               |         |
| ( <sup>¶</sup> ) Time post transplantation (years) | 1.2 (-0.6, 2.9)                               | 0.18    |                                               |         |
| ( <sup>¶</sup> ) FTI (kg/m <sup>2</sup> )          | 1.3 (-3.1, 0.6)                               | 0.19    |                                               |         |
| <b>Use of calcineurin inhibitor</b>                |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.22    |                                               |         |
| Yes                                                | 3.6 (-2.2, 9.3)                               |         |                                               |         |
| <b>Use of diuretic (furosemide)</b>                |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.23    |                                               |         |
| Yes                                                | 4.0 (-2.5, 10.5)                              |         |                                               |         |
| <b>Use of prednisolone</b>                         |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.38    |                                               |         |
| Yes                                                | -2.5 (-8.1, 3.1)                              |         |                                               |         |
| <b>Use of CCB</b>                                  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.39    |                                               |         |
| Yes                                                | 2.1 (-2.7, 6.8)                               |         |                                               |         |
| <b>Use of BAB</b>                                  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.41    |                                               |         |
| Yes                                                | 3.2 (-2.9, 6.2)                               |         |                                               |         |
| ( <sup>¶</sup> ) eGFR (mL/min)                     | -0.2 (-0.9, 0.5)                              | 0.54    |                                               |         |
| Hb (g/dL)                                          | -0.5 (-2.0, 1.1)                              | 0.56    |                                               |         |
| <b>Use of adjunctive antiproliferative agents</b>  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.56    |                                               |         |
| Yes                                                | 2.2 (-5.3, 9.7)                               |         |                                               |         |
| <b>Use of AAB</b>                                  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.56    |                                               |         |
| Yes                                                | 1.5 (-3.5, 6.5)                               |         |                                               |         |
| <b><sup>‡</sup>Smoking status</b>                  |                                               |         |                                               |         |
| Never smoked                                       | 0                                             | 0.57    |                                               |         |
| Ex-smoker / Current smoker                         | 1.4 (-3.5, 6.3)                               |         |                                               |         |
| LTI (kg/m <sup>2</sup> )                           | -0.2 (-1.0, 0.6)                              | 0.63    |                                               |         |
| ( <sup>(†)</sup> ) hsCRP (mg/L)                    | 1.1 (-3.8, 5.9)                               | 0.66    |                                               |         |
| ( <sup>(†)</sup> ) ACR (mg/mmol)                   | 0.6 (-3.0, 4.3)                               | 0.72    |                                               |         |
| <b>Previous episodes of acute rejection</b>        |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.86    |                                               |         |
| Yes                                                | -0.5 (-6.1, 5.1)                              |         |                                               |         |
| <b>R<sup>2</sup> value from final model</b>        |                                               |         | <b>62%</b>                                    |         |

<sup>§</sup>Results in the final multivariate regression model were presented.

<sup>¶</sup>CI = Confidence Interval.

<sup>†</sup>For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients respectively.

<sup>‡</sup>For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.

(<sup>¶</sup>) Coefficients reported for a 5-unit increase in explanatory variable.

(<sup>\*\*</sup>) Coefficients reported for a 10-unit increase in explanatory variable.

(<sup>\*\*\*</sup>) Coefficients reported for a 50-unit increase in explanatory variable.

(<sup>(†)</sup>) Variable analysed on the log scale (base 10).

Abbreviations: %VE=Percentage Volume Expansion; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; Alb=Albumin; FTI=Fat Tissue Index; CCB=Calcium Channel Blocker; BAB=Beta-Adrenergic Blocker; eGFR=estimated Glomerular Filtration Rate; Hb=Haemoglobin; AAB=Alpha-Adrenergic Blocker; LTI= Lean Tissue Index; hsCRP=high-sensitivity C-Reactive Protein; ACR=Albumin : Creatinine Ratio.

**Table S3. Predictors of Systolic Blood Pressure (SBP)**

|                                                    | Univariate Analysis                           |         | Multivariate Analysis <sup>§</sup>            |         |
|----------------------------------------------------|-----------------------------------------------|---------|-----------------------------------------------|---------|
|                                                    | Regression Coefficient (95% CI <sup>°</sup> ) | p-value | Regression Coefficient (95% CI <sup>°</sup> ) | p-value |
| (****) Sodium intake (mg)                          | 0.4 (0.3, 0.6)                                | <0.001  |                                               |         |
| (****) Fluid intake (mL)                           | 0.2 (0.1, 0.4)                                | <0.001  |                                               |         |
| (**) Age (years)                                   | 4.2 (2.0, 6.3)                                | <0.001  |                                               |         |
| ( <sup>†</sup> ) %VE                               | 9.7 (8.4, 11.0)                               | <0.001  | 9.8 (8.5, 11.0)                               | <0.001  |
| <b>Presence of diabetes</b>                        |                                               |         |                                               |         |
| Non-diabetic                                       | 0                                             | <0.001  |                                               |         |
| NODAT                                              | 9.2 (4.3, 14.0)                               |         |                                               |         |
| Pre-DM                                             | 23.9 (12.7, 35.0)                             |         |                                               |         |
| <b>Use of ACEI / ARB</b>                           |                                               |         |                                               |         |
| No                                                 | 0                                             | <0.01   |                                               |         |
| Yes                                                | 9.3 (2.8, 15.8)                               |         |                                               |         |
| <b>Gender</b>                                      |                                               |         |                                               |         |
| Female                                             | 0                                             | 0.02    |                                               |         |
| Male                                               | 8.1 (1.5, 14.6)                               |         |                                               |         |
| Alb (g/L)                                          | -1.1 (-2.2, -0.1)                             | 0.03    |                                               |         |
| Number of antihypertensive medications             | 3.3 (-0.5, 7.0)                               | 0.09    |                                               |         |
| <b><sup>‡</sup>Ethnicity</b>                       |                                               |         |                                               |         |
| Caucasian                                          | 0                                             | 0.20    |                                               |         |
| Non-Caucasian                                      | 5.2 (2.7, 13.1)                               |         |                                               |         |
| ( <sup>°</sup> ) FTI (kg/m <sup>2</sup> )          | -1.6 (-4.2, 1.1)                              | 0.24    |                                               |         |
| ( <sup>††</sup> ) ACR (mg/mmol)                    | 2.9 (-2.1, 8.0)                               | 0.25    |                                               |         |
| <b>Use of diuretic (furosemide)</b>                |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.28    |                                               |         |
| Yes                                                | -4.4 (-12.3, 3.5)                             |         |                                               |         |
| <b>Use of prednisolone</b>                         |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.28    |                                               |         |
| Yes                                                | -4.4 (-12.3, 3.5)                             |         |                                               |         |
| LTI (kg/m <sup>2</sup> )                           | -0.6 (-1.8, 0.5)                              | 0.28    |                                               |         |
| ( <sup>°</sup> ) Time post transplantation (years) | 1.2 (-1.2, 3.7)                               | 0.31    |                                               |         |
| Hb (g/dL)                                          | -0.9 (-3.1, 1.3)                              | 0.42    |                                               |         |
| <b>Use of calcineurin inhibitor</b>                |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.53    |                                               |         |
| Yes                                                | 2.6 (-5.6, 10.7)                              |         |                                               |         |
| <b>Use of BAB</b>                                  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.55    |                                               |         |
| Yes                                                | -2.1 (-4.4, 7.2)                              |         |                                               |         |
| <b>Previous episodes of acute rejection</b>        |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.56    |                                               |         |
| Yes                                                | -2.4 (-10.3, 5.6)                             |         |                                               |         |
| <b>Use of CCB</b>                                  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.62    |                                               |         |
| Yes                                                | 1.7 (-5.0, 8.4)                               |         |                                               |         |
| <b><sup>‡</sup>Smoking status</b>                  |                                               |         |                                               |         |
| Never smoked                                       | 0                                             | 0.69    |                                               |         |
| Ex-smoker / Current smoker                         | 1.4 (-5.5, 8.3)                               |         |                                               |         |
| ( <sup>°</sup> ) eGFR (mL/min)                     | -0.2 (-1.2, 0.8)                              | 0.71    |                                               |         |
| <b>Use of AAB</b>                                  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.74    |                                               |         |
| Yes                                                | 1.2 (-5.9, 8.3)                               |         |                                               |         |
| ( <sup>††</sup> ) hsCRP (mg/L)                     | 0.9 (-6.0, 7.8)                               | 0.80    |                                               |         |
| <b>Use of adjunctive antiproliferative agents</b>  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.95    |                                               |         |
| Yes                                                | 0.4 (-10.2, 11.0)                             |         |                                               |         |
| R <sup>2</sup> value from final model              |                                               |         | 69%                                           |         |

<sup>§</sup>Results in the final multivariate regression model were presented.

<sup>°</sup>CI = Confidence Interval.

<sup>†</sup>For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients respectively.

<sup>‡</sup>For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.

(\*) Coefficients reported for a 5-unit increase in explanatory variable.

(\*\*) Coefficients reported for a 10-unit increase in explanatory variable.

(\*\*\*) Coefficients reported for a 50-unit increase in explanatory variable.

(<sup>‡</sup>) Variable analysed on the log scale (base 10).

Abbreviations: %VE=Percentage Volume Expansion; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; Alb=Albumin; FTI=Fat Tissue Index; ACR=Albumin : Creatinine Ratio; LTI= Lean Tissue Index; Hb=Haemoglobin; BAB=Beta-Adrenergic Blocker; CCB=Calcium Channel Blocker; eGFR=estimated Glomerular Filtration Rate; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein.

**Table S4. Predictors of Diastolic Blood Pressure (DBP)**

|                                                    | Univariate Analysis                           |         | Multivariate Analysis <sup>§</sup>            |         |
|----------------------------------------------------|-----------------------------------------------|---------|-----------------------------------------------|---------|
|                                                    | Regression Coefficient (95% CI <sup>¶</sup> ) | p-value | Regression Coefficient (95% CI <sup>¶</sup> ) | p-value |
| ( <sup>¶</sup> ) %VE                               | 5.0 (3.7, 6.2)                                | <0.001  | 4.9 (3.7, 6.2)                                | <0.001  |
| ( <sup>***</sup> ) Sodium intake (mg)              | 0.2 (0.1, 0.3)                                | <0.01   |                                               |         |
| <b>Use of ACEI / ARB</b>                           |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.02    |                                               |         |
| Yes                                                | 5.3 (0.7, 9.9)                                |         |                                               |         |
| Alb (g/L)                                          | -0.8 (-1.5, -0.1)                             | 0.03    |                                               |         |
| ( <sup>**</sup> ) Age (years)                      | 1.7 (0.1, 3.3)                                | 0.04    |                                               |         |
| <b>Presence of diabetes</b>                        |                                               |         |                                               |         |
| Non-diabetic                                       | 0                                             | 0.04    |                                               |         |
| NODAT                                              | 3.7 (0.2, 7.2)                                |         |                                               |         |
| Pre-DM                                             | 4.9 (-3.6, 13.4)                              |         |                                               |         |
| <b>Gender</b>                                      |                                               |         |                                               |         |
| Female                                             | 0                                             | 0.05    |                                               |         |
| Male                                               | 4.7 (0.0, 9.3)                                |         |                                               |         |
| <b><sup>‡</sup>Ethnicity</b>                       |                                               |         |                                               |         |
| Caucasian                                          | 0                                             | 0.08    |                                               |         |
| Non-Caucasian                                      | 4.9 (-0.6, 10.4)                              |         |                                               |         |
| Number of antihypertensive medications             | 2.4 (-0.3, 5.0)                               | 0.08    |                                               |         |
| ( <sup>***</sup> ) Fluid intake (mL)               | 0.1 (-0.1, 0.2)                               | 0.16    |                                               |         |
| <b>Use of BAB</b>                                  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.16    |                                               |         |
| Yes                                                | 2.8 (-3.1, 4.8)                               |         |                                               |         |
| <b>Use of calcineurin inhibitor</b>                |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.16    |                                               |         |
| Yes                                                | 4.0 (-1.7, 9.6)                               |         |                                               |         |
| ( <sup>¶</sup> ) Time post transplantation (years) | 1.1 (-0.6, 5.6)                               | 0.21    |                                               |         |
| <b><sup>‡</sup>Smoking status</b>                  |                                               |         |                                               |         |
| Never smoked                                       | 0                                             | 0.23    |                                               |         |
| Ex-smoker / Current smoker                         | 2.9 (-1.9, 7.7)                               |         |                                               |         |
| ( <sup>¶</sup> ) FTI (kg/m <sup>2</sup> )          | -1.1 (-3.0, 0.7)                              | 0.24    |                                               |         |
| <b>Use of CCB</b>                                  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.34    |                                               |         |
| Yes                                                | 2.3 (-2.4, 7.0)                               |         |                                               |         |
| <b>Use of adjunctive antiproliferative agents</b>  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.39    |                                               |         |
| Yes                                                | 3.2 (-4.1, 10.6)                              |         |                                               |         |
| ( <sup>¶</sup> ) eGFR (mL/min)                     | -0.2 (-0.9, 0.5)                              | 0.50    |                                               |         |
| <b>Use of AAB</b>                                  |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.53    |                                               |         |
| Yes                                                | 1.6 (-3.3, 6.5)                               |         |                                               |         |
| <b>Use of diuretic (furosemide)</b>                |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.58    |                                               |         |
| Yes                                                | 1.8 (-4.6, 8.2)                               |         |                                               |         |
| <b>Use of prednisolone</b>                         |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.59    |                                               |         |
| Yes                                                | -1.5 (-7.1, 4.0)                              |         |                                               |         |
| ( <sup>(1)</sup> ) hsCRP (mg/L)                    | 1.2 (-3.6, 6.0)                               | 0.62    |                                               |         |
| ( <sup>(1)</sup> ) ACR (mg/mmol)                   | -0.6 (-4.1, 3.0)                              | 0.75    |                                               |         |
| Hb (g/dL)                                          | -0.2 (-1.7, 1.3)                              | 0.77    |                                               |         |
| <b>Previous episodes of acute rejection</b>        |                                               |         |                                               |         |
| No                                                 | 0                                             | 0.87    |                                               |         |
| Yes                                                | 0.4 (-5.1, 6.0)                               |         |                                               |         |
| LTI (kg/m <sup>2</sup> )                           | 0.0 (-0.8, 0.8)                               | 0.91    |                                               |         |
| <b>R<sup>2</sup> value from final model</b>        |                                               |         | <b>35%</b>                                    |         |

<sup>§</sup>Results in the final multivariate regression model were presented.

<sup>¶</sup>CI = Confidence Interval.

<sup>†</sup>For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients respectively.

<sup>‡</sup>For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.

(<sup>¶</sup>) Coefficients reported for a 5-unit increase in explanatory variable.

(<sup>\*\*</sup>) Coefficients reported for a 10-unit increase in explanatory variable.

(<sup>\*\*\*</sup>) Coefficients reported for a 50-unit increase in explanatory variable.

(<sup>(1)</sup>) Variable analysed on the log scale (base 10).

Abbreviations: %VE=Percentage Volume Expansion; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; Alb=Albumin; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; BAB=Beta-Adrenergic Blocker; FTI=Fat Tissue Index; CCB=Calcium Channel Blocker; eGFR=estimated Glomerular Filtration Rate; AAB=Alpha-Adrenergic Blocker; hsCRP=high-sensitivity C-Reactive Protein; ACR=Albumin : Creatinine Ratio; Hb=Haemoglobin; LTI=Lean Tissue Index.

**Table S5. Predictors of N-Terminal of prohormone B-type Natriuretic Peptide (NT-proBNP)**

|                                                   | Univariate Analysis             |         | Multivariate Analysis <sup>§</sup> |         |
|---------------------------------------------------|---------------------------------|---------|------------------------------------|---------|
|                                                   | Ratio<br>(95% CI <sup>°</sup> ) | p-value | Ratio<br>(95% CI <sup>°</sup> )    | p-value |
| <sup>(*)</sup> %VE                                | 1.38 (1.07, 1.78)               | 0.01    | 1.16 (1.03, 1.29)                  | 0.01    |
| <sup>(*)</sup> eGFR (mL/min)                      | 0.89 (0.80, 0.99)               | 0.03    | 0.95 (0.90, 0.99)                  | 0.03    |
| Hb (g/dL)                                         | 0.74 (0.57, 0.96)               | 0.03    | 0.74 (0.58, 0.96)                  | 0.02    |
| <b>Use of CCB</b>                                 |                                 |         |                                    |         |
| No                                                | 1                               | 0.09    | 1                                  | <0.01   |
| Yes                                               | 0.84 (0.53, 1.05)               |         | 0.63 (0.45, 0.89)                  |         |
| <sup>(†)</sup> ACR (mg/mmol)                      | 1.24 (0.96, 1.60)               | 0.10    |                                    |         |
| <b>Use of adjunctive antiproliferative agents</b> |                                 |         |                                    |         |
| No                                                | 1                               | 0.11    |                                    |         |
| Yes                                               | 0.85 (0.40, 1.10)               |         |                                    |         |
| <b><sup>‡</sup>Smoking status</b>                 |                                 |         |                                    |         |
| Never smoked                                      | 1                               | 0.12    | 1                                  | 0.03    |
| Ex-smoker / Current smoker                        | 1.16 (0.93, 1.84)               |         | 1.46 (1.04, 2.05)                  |         |
| LTI (kg/m <sup>2</sup> )                          | 0.96 (0.91, 1.02)               | 0.20    |                                    |         |
| <sup>(**)</sup> Age (years)                       | 1.20 (0.91, 1.59)               | 0.20    |                                    |         |
| <sup>(*)</sup> Time post transplantation (years)  | 1.20 (0.91, 1.60)               | 0.20    |                                    |         |
| <b><sup>‡</sup>Ethnicity</b>                      |                                 |         |                                    |         |
| Caucasian                                         | 1                               | 0.21    |                                    |         |
| Non-Caucasian                                     | 0.56 (0.23, 1.40)               |         |                                    |         |
| <b>Use of prednisolone</b>                        |                                 |         |                                    |         |
| No                                                | 1                               | 0.29    |                                    |         |
| Yes                                               | 0.17 (0.01, 4.75)               |         |                                    |         |
| <sup>(†)</sup> hsCRP (mg/L)                       | 0.83 (0.58, 1.19)               | 0.31    |                                    |         |
| <b>Gender</b>                                     |                                 |         |                                    |         |
| Female                                            | 1                               | 0.33    |                                    |         |
| Male                                              | 0.68 (0.32, 1.47)               |         |                                    |         |
| <b>Use of AAB</b>                                 |                                 |         |                                    |         |
| No                                                | 1                               | 0.41    |                                    |         |
| Yes                                               | 1.09 (0.82, 1.64)               |         |                                    |         |
| <b>Presence of diabetes</b>                       |                                 |         |                                    |         |
| Non-diabetic                                      | 1                               | 0.42    |                                    |         |
| NODAT                                             | 2.02 (0.69, 5.96)               |         |                                    |         |
| Pre-DM                                            | 1.32 (0.37, 4.70)               |         |                                    |         |
| <b>Use of BAB</b>                                 |                                 |         |                                    |         |
| No                                                | 1                               | 0.45    |                                    |         |
| Yes                                               | 0.98 (0.81, 1.28)               |         |                                    |         |
| <b>Use of calcineurin inhibitor</b>               |                                 |         |                                    |         |
| No                                                | 1                               | 0.48    |                                    |         |
| Yes                                               | 1.44 (0.52, 4.01)               |         |                                    |         |
| <sup>(***)</sup> Fluid intake (mL)                | 1.07 (0.86, 1.33)               | 0.53    |                                    |         |
| Number of antihypertensive medications            | 0.95 (0.79, 1.16)               | 0.63    |                                    |         |
| Alb (g/L)                                         | 1.03 (0.91, 1.17)               | 0.67    |                                    |         |
| <b>Use of diuretic (furosemide)</b>               |                                 |         |                                    |         |
| No                                                | 1                               | 0.81    |                                    |         |
| Yes                                               | 1.02 (0.67, 1.67)               |         |                                    |         |
| <b>Use of ACEI / ARB</b>                          |                                 |         |                                    |         |
| No                                                | 1                               | 0.90    |                                    |         |
| Yes                                               | 1.05 (0.48, 2.28)               |         |                                    |         |
| <sup>(*)</sup> FTI (kg/m <sup>2</sup> )           | 1.01 (0.88, 1.15)               | 0.95    |                                    |         |
| <sup>(***)</sup> Sodium intake (mg)               | 1.01 (0.84, 1.20)               | 0.95    |                                    |         |
| <b>Previous episodes of acute rejection</b>       |                                 |         |                                    |         |
| No                                                | 1                               | 0.98    |                                    |         |
| Yes                                               | 1.01 (0.36, 2.89)               |         |                                    |         |
| <b>R<sup>2</sup> value from final model</b>       |                                 |         | <b>21%</b>                         |         |

<sup>§</sup>Results in the final multivariate regression model were presented.

<sup>°</sup>CI = Confidence Interval.

<sup>†</sup>For the purpose of statistical analysis, smoking status was arranged into 2 categories, “non-smoker” versus “the combination of current smoker and ex-smoker”, 63% and 37% of patients respectively.

<sup>‡</sup>For the purpose of statistical analysis, the ethnicity of patients classified as “Afro-Caribbean”, “Asian” and “Others” was grouped as “Non-Caucasian”, 77% “Caucasian” versus 23% “Non-Caucasian”.

<sup>(\*)</sup> Coefficients reported for a 5-unit increase in explanatory variable.

<sup>(\*\*)</sup> Coefficients reported for a 10-unit increase in explanatory variable.

<sup>(\*\*\*)</sup> Coefficients reported for a 50-unit increase in explanatory variable.

<sup>(†)</sup> Variable analysed on the log scale (base 10).

Abbreviations: NT-proBNP=N-Terminal pro B-type Natriuretic Peptide; %VE=Percentage Volume Expansion; eGFR=estimated Glomerular Filtration Rate; Hb=Haemoglobin; CCB=Calcium Channel Blocker; ACR=Albumin : Creatinine Ratio; LTI= Lean Tissue Index; hsCRP=high-sensitivity C-Reactive Protein; AAB=Alpha-Adrenergic Blocker; NODAT=New Onset Diabetes After Transplantation; Pre-DM=Presence of Diabetes Mellitus pre-transplantation; BAB=Beta-Adrenergic Blocker; Alb=Albumin; ACEI=Angiotensin-Converting-Enzyme Inhibitor; ARB=Angiotensin-Receptor Blocker; FTI=Fat Tissue Index.